within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB13_AsfotaseAlfa;

model AsfotaseAlfa
  extends Pharmacolibrary.Drugs.ATC.A.A16AB13;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A16AB13</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Asfotase alfa is a recombinant human tissue-nonspecific alkaline phosphatase enzyme replacement therapy indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP), a rare genetic disorder characterized by defective bone mineralization due to deficient activity of alkaline phosphatase. It is an approved medication for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in pediatric and adult patients with hypophosphatasia, based on population PK studies and summary data from clinical trials.</p><h4>References</h4><ol><li><p>Pan, WJ, et al., &amp; Seefried, L (2021). Pharmacokinetics of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia. <i>Journal of clinical pharmacology</i> 61(10) 1334â€“1343. DOI:<a href=\"https://doi.org/10.1002/jcph.1870\">10.1002/jcph.1870</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33822385/\">https://pubmed.ncbi.nlm.nih.gov/33822385</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end AsfotaseAlfa;
